Will a Big Pharma company swoop in to acquire Vivus ($VVUS), now that its obesity drug Qnexa has an FDA advisory panel's recommendation? Analysts say Bristol-Myers Squibb ($BMY), Merck ($MRK), and Johnson & Johnson ($JNJ) could be hungry for the potential blockbuster, but doubters point to the possibility of FDA requiring a cardiac safety study. Report